Evolving Glaucoma Care: Dr. Aaron Kuzin, MD, Shares His Experience with iDose® TR and Interventional Glaucoma

Provider Newsletter

By Sight Partners Glaucoma management continues to evolve as new technologies and treatment strategies emerge to address one of the most persistent challenges in eye care: preventing vision loss despite good medical therapy. In a recent Sight Partners webinar, Dr. Aaron Kuzin, MD shared his real-world experience and early outcomes with the iDose® TR sustained-release…

Read More
Image of Dr. Kuzin, MD with the text: "From Trials to Treatment"

Pediatric Blepharokeratoconjunctivitis

Provider Newsletter,Uncategorized

Pediatric Blepharokeratoconjunctivitis Pediatric blepharokeratoconjunctivitis (BKC) winds up in my chair way more than I would have predicted when I left optometry school. Our clinic sees this so much, we even have a drop-down phrase in our electronic record system for diagnosis and plan that we can adjust. This condition is a chronic inflammatory disease stemming…

Read More

Healthy Aging Eyes

Aging Eyes,Glaucoma,Provider Newsletter,Uncategorized

While no ocular fountain of youth exists and not all eye conditions are preventable, one of our most important roles as eye clinicians is helping the public maintain their vision and ocular health as they age.  Unfortunately, there is still the idea among the public that if one has good vision, then they don’t need…

Read More

Thyroid Eye Disease – No More NO SPECS

Provider Newsletter,Thyroid Eye Disease

  Thyroid eye disease is an autoimmune condition affecting the ocular tissues. It occurs in up to 25% of patients with Graves’ disease. It is most common in patients who have hyperthyroidism (Graves’ disease), however, it can also occur under eurthyroid (10%) or autoimmune mediated hypothyroid conditions. Thyroid eye disease is more common in women,…

Read More

Northwest Eye Clinical Research Update: The Glaukos iDose GC-012 Study

iDose GC-012 Study,Provider Newsletter,Uncategorized

  Study Overview Northwest Eye Surgeons is happy to announce that Drs. Cameron and Kuzin are Principal Investigators in an active FDA approved Phase III clinical study on iDose Travoprost Intraocular Implants.  This is a prospective, randomized masked three year study comparing novel implantable glaucoma medication delivery devices to topical timolol.  One of two biocompatible…

Read More

Angle Closure

Glaucoma,Provider Newsletter,Uncategorized

According to the World Health Organization, glaucoma is the leading cause of preventable blindness worldwide. Glaucoma can be subdivided into two types based on anterior segment anatomy: open-angle glaucoma or angle-closure glaucoma. While open-angle glaucoma is the significantly more prevalent form of the two, angle-closure glaucoma is more likely to cause bilateral blindness. Angle closure…

Read More